Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Acute myeloid leukemias (AMLs) are overlapping hematological neoplasms associated with
rapid onset, progressive, and frequently chemo-resistant disease. At diagnosis, classification …

Risk stratification in acute myeloid leukemia (AML) remains principle in survival
prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) …

Abstract The revised 2022 European LeukemiaNet (ELN) AML risk stratification system
requires validation in large, homogeneously treated cohorts. We studied 1118 newly …

Abstract Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of
acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with …

Identifying mechanisms underlying relapse is a major clinical issue for effective cancer
treatment. The emerging understanding of the importance of metastasis in hematologic …

Allogeneic stem-cell transplant allows for the delivery of curative graft-versus-leukemia
(GVL) in patients with acute myeloid leukemia/myelodysplasia (AML/MDS). Surveillance of T …

NPM 1-mutated acute myeloid leukemia (AML) shows unique features. However, the
characteristics of “therapy-related” NPM1-mutated AML (t-NPM1 AML) are poorly …

Revised diagnostic criteria for myeloid neoplasms (MN) issued by the International
Consensus Classification (ICC) and the World Health Organization (WHO) recommended …

Acute myeloid leukemia (AML) is a major hematopoietic malignancy characterized by the
accumulation of immature and abnormally differentiated myeloid cells in bone marrow. Here …